Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Therapeutics, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. As of December 9, 2025, Akero Therapeutics, Inc. operates as a subsidiary of Novo Nordisk A/S.
Часто задаваемые вопросы
В каком секторе работает Akero Therapeutics, Inc (AKRO)?
Akero Therapeutics, Inc относится к сектору Здравоохранение.
Какова текущая цена акций Akero Therapeutics, Inc (AKRO)?
По последним данным, цена акций Akero Therapeutics, Inc составляет 54,65 $, предыдущее закрытие — 54,65 $.
Выплачивает ли Akero Therapeutics, Inc (AKRO) дивиденды?
Нет, Akero Therapeutics, Inc не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Akero Therapeutics, Inc (AKRO)?
У компании Akero Therapeutics, Inc бета -0.404, что указывает на более низкую волатильность по сравнению с рынком в целом.
